Literature DB >> 29249233

Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
.

David Dado, Samir Parikh, Isabelle Ayoub, Brad Rovin, Tibor Nadasdy, Lee Hebert.   

Abstract

A unique characteristic of the response of minimal-change disease (MCD) or focal and segmental glomerulosclerosis (FSGS) to steroid therapy is that the remission of proteinuria occurs quickly, for example, within 4 - 6 weeks of the onset of steroid therapy, even in those with severe nephrotic syndrome. Remission of proteinuria in MCD and FSGS can also occur spontaneously (not steroid induced). However, spontaneous remission usually proceeds over several months or longer. Recently, there have been several reports that abatacept can induce proteinuria remission in MCD and FSGS. These claims, however, are dubious because either the remission occurred slowly over several months of abatacept therapy, or remission occurred within a few weeks of abatacept therapy, but the patient was also receiving therapies that could have accounted for the remission of proteinuria. Our case is unique in that his severe steroid- and cyclosporine-resistant MCD remitted acutely while receiving abatacept, and there was no other plausible explanation for the acute remission of his MCD.
.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29249233     DOI: 10.5414/CN109290

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

Review 1.  The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease.

Authors:  Hai Ning Wee; Jian-Jun Liu; Jianhong Ching; Jean-Paul Kovalik; Su Chi Lim
Journal:  Am J Nephrol       Date:  2021-11-09       Impact factor: 3.754

Review 2.  IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.

Authors:  Agnes Trautmann; Marina Vivarelli; Susan Samuel; Debbie Gipson; Aditi Sinha; Franz Schaefer; Ng Kar Hui; Olivia Boyer; Moin A Saleem; Luciana Feltran; Janina Müller-Deile; Jan Ulrich Becker; Francisco Cano; Hong Xu; Yam Ngo Lim; William Smoyer; Ifeoma Anochie; Koichi Nakanishi; Elisabeth Hodson; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2020-05-07       Impact factor: 3.714

3.  CTLA4-Ig Abatacept Ameliorates Proteinuria by Regulating Circulating Treg/IL-17 in Adriamycin-Induced Nephropathy Rats.

Authors:  Lanjun Shuai; Qia Cheng; Tian Shen; Zhuwen Yi; Xiaochuan Wu
Journal:  Biomed Res Int       Date:  2020-04-25       Impact factor: 3.411

4.  Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity.

Authors:  Anatilde M Gonzalez Guerrico; John Lieske; George Klee; Sanjay Kumar; Victor Lopez-Baez; Adam M Wright; Shane Bobart; Diane Shevell; Michael Maldonado; Jonathan P Troost; Marie C Hogan
Journal:  Kidney Int Rep       Date:  2020-08-14

Review 5.  Management of Steroid-Resistant Nephrotic Syndrome in Children.

Authors:  Sanjana Sachdeva; Syeda Khan; Cristian Davalos; Chaithanya Avanthika; Sharan Jhaveri; Athira Babu; Daniel Patterson; Abdullah J Yamani
Journal:  Cureus       Date:  2021-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.